Tag: pharmaceuticals

  • Drug Companies Urged to Conserve Antibiotics to Fight Resistance

    A new report recommends that pharmaceutical companies take a different approach to combating resistance to antibiotic drugs. An article published today in the journal Health Affairs suggests physicians, hospitals, and drug makers coordinate their practices to extend the effective lifetimes of antibiotics. The paper, by Aaron S. Kesselheim of Brigham and Women’s Hospital and Harvard…

  • European Approval Sought for Daily HIV Treatment

    Gilead Sciences Inc. of Foster City, California is seeking approval to market a combination of its Truvada drug with Tibotec Pharmaceuticals’ TMC278 as a single-dose daily treatment for HIV infection. If approved, the new single-tablet regimen would be only the second product that contains a complete antiretroviral treatment regimen in a single once-daily tablet, according…

  • Trial Shows Drug Reduces Lactic Acid in Trauma Patients

    Results from a proof-of-concept clinical trial of the drug MP4OX in severely injured trauma patients with hemorrhagic shock showed that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients. MP4OX is an oxygen therapeutic agent that is designed to provide rapid oxygen delivery to tissues with…

  • Patent Awarded for Drug Spray/Dispersion Technology

    Bend Research Inc., a developer of drug formulation technology in Bend, Oregon, says it received a U.S. patent covering a process for making spray-dried solid amorphous dispersions of drugs using pressure nozzles. The patent — No. 7,780,988 assigned by the U.S. Patent and Trademark Office — covers a spray-drying process for producing solid amorphous dispersions…

  • FDA Approves New Blood Pressure Drug

    The U.S. Food and Drug Administration (FDA) approved the drug Tekamlo to treat high blood pressure, made by pharmaceutical manufacturer Novartis of East Hanover, New Jersey. Tekamlo tablets combine the renin inhibitor aliskiren with the calcium channel blocker amlodipine. FDA approved Tekamlo as an initial therapy for patients who are likely to need multiple drugs…

  • Clinical Trial of Heart Failure Drug Underway Soon

    Cardioxyl Pharmaceuticals Inc. in Chapel Hill, North Carolina, today announced the start of clinical trial of its lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure (ADHF). The trial will help define proper dosing for the drug. Cardioxyl’s placebo-controlled phase 2-a trial will take place in as many as 20 sites in…

  • Aileron, Roche to Partner on Peptide Drug Delivery

    Aileron Therapeutics in Cambridge, Massachusetts announced today a partnership with the Swiss pharmaceutical company Roche to develop and commercialize a new class of drugs called stapled peptide therapeutics. Roche and Aileron will develop drug candidates with this technology for up to five targets in Roche’s fields of expertise: oncology, virology, inflammation, metabolism, and central nervous…

  • Biotech Researchers Publish Parkinson’s Gene Silencing Data

    Researchers from Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts, collaborating with colleagues at research institutes, reported effective silencing of a gene associated with Parkinson’s Disease. The pre-clinical findings were published 11 August in the journal Public Library of Science (PLoS). The researchers silenced the alpha-synuclein gene using an RNA interference (RNAi) therapeutic administered directly to the…

  • Symposium Reports on Open Source Drug Discovery

    A day-long symposium today at the American Chemical Society national meeting in Boston, Massachusetts reports on efforts to lift the secrecy often surrounding drug discovery. This new approach known as open-source drug discovery connects an online worldwide community that collaborates on discovering and developing new drugs. This combination of movement and work program has the…

  • FDA Grants Orphan Status for Neuromuscular Drug

    Acceleron Pharma, Inc., a biopharmaceutical company in Cambridge, Massachusetts, today said the U.S. Food and Drug Administration (FDA) granted ACE-031, its treatment for Duchenne Muscular Dystrophy (DMD), with an orphan drug designation. DMD is a debilitating and fatal genetic disorder characterized by the progressive loss of muscle strength and function. The disease affects mainly boys…